Tricyclic inhibitors of matrix metalloproteinases
US5958972A · kind A · utility
12Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 1997 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | May 20, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D307/91
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Tricyclic compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.